UK markets closed
NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.72 -0.91 (-1.10%) GOLD FUTURES
2,304.80 -52.90 (-2.24%) DOW
38,007.91 -378.18 (-0.99%) Bitcoin GBP
50,119.69 -539.11 (-1.06%)
Regeneron Pharmaceuticals, Inc. (0R2M.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
At close: 06:20PM BST
| Previous close | 892.94 |
| Open | 894.53 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 885.00 - 895.50 |
| 52-week range | 689.00 - 998.57 |
| Volume | |
| Avg. volume | 1,962 |
| Market cap | 993.865M |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | 0.13 |
| EPS (TTM) | 70.31 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksWill These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
ZacksShould You Consider Regeneron (REGN) Ahead of Q1 Earnings?
An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.
ZacksDown -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround
Regeneron (REGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
© 2024 Yahoo. All rights reserved.